PASADENA, Calif. PASADENA, Calif. Xencor Inc. on Tuesday reported a loss of $19.1 million in its fourth quarter. The Pasadena, California-based company said it had a loss of 31 cents.
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
– Prior data from the Phase 2 SOLSTICE trial in chronic hepatitis delta participants demonstrated that after only 12 weeks of combination therapy, 100% of participants had HDV RNA less than the.
Xencor, Inc. , a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that it will report.